



— COMPOUNDING PHARMACY

Model42 Compounding Pharmacy

Personalised medicine infrastructure connecting structured data,
licensed clinical judgement and patient-specific compounding.

POWERED BY



— EXECUTIVE PROPOSITION

One connected pathway makes personalised medicine scalable



Structured intake



Targeted diagnostics



AI-supported review



Physician decision



Prepare, deliver & monitor

One accountable pathway. Licensed professionals retain clinical and pharmaceutical authority.

Personalised care breaks down when data, decisions and delivery sit in separate workflows



FRAGMENTED ENTRY POINTS

Questionnaires, tests, physicians and pharmacies are often disconnected.



UNSTRUCTURED CLINICAL DATA

History, goals, risk factors and laboratory results arrive in different formats.




WEAK FOLLOW-UP

Treatment can become a transaction rather than a monitored clinical cycle.

The unmet need is one accountable pathway from intake to reassessment.

One operating system unifies the patient experience, clinical governance and licensed compounding



PATIENT EXPERIENCE

-  Digital medical questionnaire
-  Mobile diagnostics through partner laboratories
-  Delivery, guidance and repeat monitoring


MODEL42

INNOVATE. INVEST. EXTEND.

ACCOUNTABLE OPERATING LAYER

-  AI clinical decision support
-  Final decision by a licensed physician
-  Licensed pharmacy preparation

One end-to-end pathway — from structured intake to physician-led reassessment



AI supports the pathway. Diagnosis and treatment decisions remain with the licensed physician.

Structured intake creates the clinical data foundation before any protocol is considered



GOALS & CURRENT CONCERNS

Symptoms, objectives and baseline



MEDICAL HISTORY

Conditions, procedures, family history and relevant risks



MEDICATIONS & ALLERGIES

Medicines, supplements, allergies and contraindication flags



RISK & CONSENT

Identity, consent, red flags and items requiring physician review

AI organises the information. It does not diagnose or prescribe.



Diagnostics are coordinated around the patient's schedule



HOME

Home sample collection

A licensed laboratory partner manages collection, identification and transport.



OFFICE

Workplace collection

Testing can be scheduled around work, travel and clinical requirements.




OTHER LOCATION

By appointment

Available locations and test menus depend on the appointed local laboratory.

AI turns fragmented inputs into a structured case for physician review



THE GOVERNANCE PRINCIPLE

AI does not diagnose or prescribe. The licensed physician retains final clinical authority.

— CLINICAL GOVERNANCE

Clinical authority stays with the physician



Structures data and highlights missing information



Identifies patterns and potential risk relationships




Prepares draft protocol logic for review



Does not diagnose or prescribe


The licensed physician consults, decides, prescribes when required and directs follow-up.

The protocol is designed around the patient's evidence — not selected from a generic menu



Availability depends on jurisdiction, lawful indication and pharmacy acceptance.

A valid clinical order enters a controlled pharmacy preparation and release workflow



Preparation and pharmaceutical release remain with the licensed compounding pharmacy.

The supplied materials cover several peptide families and delivery formats



RECOVERY & TISSUE SUPPORT

BPC-157, TB-4 / TB-500 and listed combinations



METABOLIC & MITOCHONDRIAL

AOD-9604, MOTS-C, Humanin, SS-31 and NAD+



NEUROCOGNITIVE & SLEEP

Selank, Semax and DSIP



ENDOCRINE & REPRODUCTIVE

CJC-1295, Ipamorelin, Kisspeptin and hCG



IMMUNE & INFLAMMATION

Thymosin alpha-1, KPV and listed combinations



DELIVERY FORMATS

Prefilled pens, sprays, vials and cartridges

Catalogue inclusion is not a claim of approval, availability, efficacy or suitability.

Follow-up gives the physician evidence for the next decision



ADHERENCE

Whether the protocol can be followed correctly



BIOMARKERS

Relevant measures compared with baseline



REPEAT TESTING

Diagnostics scheduled through clinical judgement



TOLERABILITY

Symptoms, complaints and safety review



GOAL PROGRESS

Clinical objectives reviewed without outcome promises



PHYSICIAN ADJUSTMENT

Continue, modify or stop through the licensed clinician

Monitoring converts a one-off order into a governed clinical cycle.

Revenue can be built across implementation, technology and compliant operating support



IMPLEMENTATION & MARKET SET-UP

Localisation, workflow design, partner onboarding and launch support



PLATFORM & DECISION-SUPPORT TOOLS

Questionnaire, data layer and clinical workflow software



FRANCHISE / LICENCE & SUPPORT

Brand rights, SOP, training, standards and continuing support



SERVICES & ORDER COORDINATION

Laboratory, pharmacy and fulfilment coordination where lawful

To validate: franchise fee, royalty, capex, gross margin, working capital and payback.

A governed personalised-medicine system for licensed local operators



MEDICAL CENTRES & CLINICS

Existing clinical infrastructure and patient access



PHARMACIES & OPERATORS

Pharmaceutical governance and local fulfilment capability



HEALTHCARE INVESTORS

Capital plus a qualified licensed operating partner



MASTER FRANCHISE PARTNERS

Multi-site and territorial capacity

Territorial rights depend on contract, milestones and local approvals.

The franchise system combines brand, technology, clinical workflow and operating support



BRAND & MARKET RIGHTS

Approved Model42 Compounding Pharmacy brand rights



DIGITAL FOUNDATION

Questionnaire, platform and data workflow



AI SUPPORT LAYER

Structured case review and risk flags



CLINICAL OPERATING SYSTEM

Customer journey, SOP and physician governance



PARTNER ONBOARDING

Physician, laboratory and pharmacy onboarding




QUALITY & GROWTH SUPPORT

Training, QA, technology, operations and marketing


Territorial exclusivity may be considered subject to contract, milestones and local approvals.

Each market is built around a compliant operating model — not a copied template



Outcome: a documented operating model, transparent economics and a decision on expansion.

A validated pilot can scale into a regional network



EACH STAGE REMOVES EXECUTION RISK

Brand reach → operating knowledge → procurement leverage → consistent quality.

The moat is the integrated operating layer — not access to peptide supply




DATA & WORKFLOW STANDARDS

Structured intake, interoperable records and auditable operations



CLINICAL GOVERNANCE

AI support is separated from physician and pharmacy authority



MODEL42
INNOVATE. INVEST. EXTEND.

MODEL42 OPERATING SYSTEM

LICENSED NETWORK

Physicians, laboratories, pharmacies and local operators



FRANCHISE REPLICATION

SOP, training, quality assurance and master-franchise expansion



Supplied UAE documents support licensed compounding; Model42 remains the orchestration layer



LICENSED PHARMACY EVIDENCE

MOHAP GMP certificate • Dubai trade licence

Current status must be reverified before launch.



MODEL42 OPERATING ROLE

Platform design • market entry • partner orchestration

Physicians and laboratories appointed market by market.

Move from market interest to a structured feasibility decision



MARKET PARTNER

Licensed operator and target market



FEASIBILITY DESIGN

Validate regulation, patient pathway, partners and economics



CONTROLLED LAUNCH

Localise, train and pilot before expansion

Medical, regulatory and commercial boundaries are built into the model

MEDICAL & AI

-  This presentation is not medical advice.
-  AI provides decision support only; the licensed physician makes the final clinical decision.
-  Preparation and dispensing remain with licensed entities against a valid prescription or lawful order.

REGULATORY & COMMERCIAL

-  Permitted claims and licences vary by jurisdiction.
-  Franchise rights require due diligence, contracts and regulatory approvals.
-  No investment return, margin or payback is promised; all economics require confirmation.

— CONTACT

Build the personalised medicine pathway for your market

OFFICE

ICTS Training Center · 25A St, Al Quoz Industrial Area 3 · Dubai, UAE

WEBSITE

healthlab42.ae

EMAIL

info@model42.ae

POWERED BY

